Antiviral activity of primary human trophoblast conditioned media against rift valley fever virus. by Berback, Jonathan T
ANTIVIRAL ACTIVITY OF PRIMARY HUMAN TROPHOBLAST CONDITIONED MEDIA 
AGAINST RIFT VALLEY FEVER VIRUS 
by 
Jonathan T. Berback 
BS, Moravian College, 2013 
Submitted to the Graduate Faculty of 
the Department of Infectious Diseases and Microbiology 
the Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of 
Master of Public Health  
University of Pittsburgh 
2015 
ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
This thesis was presented 
by 
Jonathan T. Berback 
It was defended on 
November 19, 2015 
and approved by 
Thesis Advisor: 
Amy L. Hartman, PhD, Assistant Professor, Infectious Diseases and Microbiology, 
Graduate School of Public Health, University of Pittsburgh
Commitee Member:
 Douglas Reed, PhD, Assistant Professor, Infectious Diseases and 
Microbiology, Graduate School of Public Health, University of Pittsburgh 
Commitee Member:
Velpandi Ayyavoo, Professor and Assistant Chair, Infectious Diseases and 
Microbiology, Graduate School of Public Health, University of Pittsburgh 
 iii 
Copyright © by Jonathan T. Berback 
2015 
 iv 
 
ABSTRACT 
Rift Valley Fever Virus (RVFV) is a Phlebovirus that is found across most of Africa with 
the majority of cases coming from eastern Africa near Egypt to as far south as South Africa and 
is a significant public health concern. Aedes mosquitos are the primary vectors of the disease, 
and as a consequence of this cases are more common after heavy rainfall or flooding. RVFV 
primarily infects domesticated ruminants, and epidemics are characterized by abortion storms 
among livestock. During these epidemics, people inevitably come into contact with infected 
tissues and these people are at the highest risk for zoonosis. Domestic ruminants are not the only 
animals at risk for spontaneous abortion or juvenile death; wild ruminants and other animals also 
develop similar outcomes. RVFV is known to cause extensive fetal loss in animals but a similar 
outcome in cases of human infections is not well documented. Two published case reports exist 
which suggest vertical transmission events could occur in humans. Currently there are only 
speculative in vitro models investigating the potential for the vertical transmission of RVFV 
have been demonstrated. Primary Human Trophoblasts (PHT) cells isolated from human 
placentas could serve as a good model for a vertical transmission event because these cells serve 
as a physical barrier to the placenta and have also been shown to be resistant to viral infection. 
PHT cells express a very unique cluster of miRNA’s located on chromosome 19 and the 
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expression of these miRNA’s is specific to pregnancy with expression dropping off shortly after 
birth. The viral resistance seen in PHT cells can also be conferred to other cell types. One 
possible way that viral resistance can be conferred to other cell types is via exosome. Since 
RVFV is of public health concern and potentially associated with fetal infections in humans, we 
will test the ability of primary human trophoblast conditioned media (PHTCM) to confer viral 
resistance to other cell types against RVFV. 
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1.0  INTRODUCTION 
Rift valley fever virus (RVFV) is an enveloped, single stranded negative sense RNA 
virus which belongs to the Bunyaviridae family and the Phlebovirus genus1. The RVFV 
genome is composed of three segments that are designated L, M and S of negative or 
ambisense polarity. The L segment of the genome encodes the viral RNA-dependent RNA 
polymerase. The M segment encodes for the surface glycoproteins annotated Gn and Gc  as well 
as NSm 1 and 2. Finally the S segment is ambisense allowing it to code for the nucleoprotein N 
and the non-structural protein NSs 9. The complete viral particle measures 90-110 nm in 
diameter and has a lipid membrane that presents two glycoproteins 9.  
The geographic distribution of RVFV encompasses most of Africa from Egypt to South 
Africa with the majority of reports coming from eastern and southern Africa. Aedes mosquitos 
are the primary vectors, and cases of RVFV are particularly prominent during times of unusually 
heavy rainfall and flooding. RVFV infects livestock as well as humans with the most dramatic 
impact being observed on livestock in the form of spontaneous abortion and juvenile death. 
These “abortion storms” affect nearly 100% of pregnant animals during an epidemic1. 
Currently, the clinical disease phenotype that leads to vertical transmission and abortion 
in livestock has not been well characterized in humans 8. There are two cases documented, one in 
2006 and the other in 2008, which were suspected to be vertical transmission events of RVFV 
from mother to child 3,4. 
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1.1 RIFT VALLEY FEVER VIRUS 
1.1.1 Epidemiology  
Rift Valley Fever (RVF) is a mosquito-borne viral zoonosis that was first isolated and 
characterized in 1931 in Kenya 14. RVFV zoonosis occurred primarily in Kenya until the disease 
was recognized in South Africa in 1951, when humans became ill after handling dead and 
infected animals. More cases were later confirmed in Zimbabwe, Zambia, the Sudan, and other 
east African countries. In 1977, there was a major epidemic in Egypt, with 20–40,000 human 
clinical illnesses and 600 human deaths. RVF was then identified in West Africa in Senegal and 
Mauritania, where human mortality was again high. In 2000, an outbreak occurred in Saudi 
Arabia marking the first occurrence RVFV outside Africa 13. During 2007 a large RVF outbreak 
occurred in Sudan with a total of 747 confirmed human cases including 230 deaths, although it is 
thought that over 75,000 were infected during this time. The outbreak was most severe near the 
White Nile and the Blue Nile Rivers 16. 
1.1.2 Transmission  
Mosquitoes in the Aedes genus have been considered as the reservoir, as well as vectors, 
since their transovarially infected eggs withstand desiccation and larvae hatch when in contact 
with water. However, different mosquito species can serve as vectors for RVF, creating a 
complex epidemiologic pattern in East Africa10. Currently RVFV has been isolated from over 30 
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species of mosquitoes in six genera 15. Infection by RVF usually spreads among livestock first 
through mosquito bites. In addition, the infection can also be transmitted vertically between 
domesticated animals11. Examples of human exposures associated with acute RVF infection 
include animal contact, consuming or handling products from sick animals, consuming raw milk, 
milking, skinning, slaughtering, sleeping with animal herds, touching blood, and caring for 
animals during birthing, and socio-demographic factors (male gender and herdsperson 
occupation), Non-animal related risks include living in proximity to water sources and having a 
flooded home17. RVFV has also been shown to be highly infectious via aerosol although the 
extent of the role it plays in epidemics is unknown1. 
1.1.3 Pathogenesis  
Human infection with RVFV is generally asymptomatic, and the majority of those with 
clinical symptoms present with a short febrile illness21. The incubation period for RVFV is 2 to 6 
days and symptoms start abruptly with severe chills, malaise, dizziness, weakness, severe 
headache and nausea but usually resolve without sequelae2. Some of those cases result in 
recurring fevers with headaches for up to 10 days followed by two weeks of weakness before 
recovery21. A subset of infected patients will develop severe forms of disease including 
neurological disorders, vision loss, hemorrhagic fever and thrombosis. The overall fatality rate is 
estimated at 0.5-1% but in patients whose severe clinical outcomes the fatality rate has been 
reported to be as high as 29%20.  
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1.2 RIFT VALLEY FEVER AND HUMAN PREGNANCY 
1.2.1 Background 
It is important to highlight the fact that aborted fetal materials and placental membranes 
could contain large numbers of virus particles capable of contaminating the local environment 
directly or infect animals in close contact9. Since animals accumulate large numbers of viral 
particles in their placentas then the question is whether or not we see something similar in 
humans. Human placentas potentially have a unique mechanism for protecting the fetus from 
viral infection.  
During the 2000–2001 RVFV outbreak in the Arabian Peninsula, no child under the age 
of 10 years old was confirmed to have died as a result of RVFV infection. The underlying 
difference in susceptibility of young and pregnant animals with that observed in humans requires 
further study and raises an important question: are the dramatic differences in lethality the result 
of a lack of contact of children with infected mosquitoes or infected animals or are there true 
differences in susceptibility between young animals and young children 9? 
1.2.2 Case Reports 
In 2006, a paper was published documenting a 5-day-old child who was admitted to 
intensive care with sepsis in September of 2000. The parents reported fever, difficulty breathing, 
and diminished activity on day 2 of life. The child was born at home in an area of Saudi Arabia 
affected by the ongoing RVFV outbreak. The mother was ill 4 days before delivery with 
symptoms including fever, headache, muscle aches, and dizziness. Six out of the nine family 
members of the mothers’ family also became ill in the two weeks prior to her delivery, and the 
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grandfather even died of a confirmed RVF case. The family also owned sheep and goats that 
everyone had contact with during the epidemic resulting in their animals becoming ill and 
aborting. The child succumbed to disease with symptoms such as an enlarging liver, 
coagulopathy, anemia, poor liver function and RVFV-IgG positive. Since RVFV-IgM, which is 
not passed across the placenta, was positive in the child on the second day of life, it is strongly 
suspected that this was a case of vertical transmission from the mother3. 
In 2008, a second case report documents a pregnant Sudanese woman. The woman 
delivered a baby with an Apgar score of 5/10; the baby had a palpable liver and spleen as well as 
a skin rash. Samples were taken from the mother and the neonate both of whom tested positive 
for RVF-IgM. On the third day of life the neonate developed clinical jaundice and unfortunately 
it was at this point that the husband went against medical advice and discharged the mother and 
child from the hospital. This paper also includes an interesting comment stating that severe forms 
of RVFV with high maternal mortality have been observed in central Sudan but that the work 
remains unpublished4. 
1.2.3 Primary Human Trophoblast Cells 
Primary human Trophoblasts (PHT) derived from human placentas may be useful in 
generating a model that represents trans-placental RVFV infection in humans. While PHT cells 
are known to form the physical barrier of the placenta, it is not well understood how they 
influence viral infections. PHT cells have not only been demonstrated to be resistant to viral 
infection, but their resistance can be conferred to nontrophoblast cells when incubated with 
conditioned medium from PHT cells5, 6.  This affect has been shown with viruses including HIV, 
VZV, EEEV, VEEV, CHIKV, SINV, Rubella, CVB, PV, VSV, VV, HSV-1 and CMV5, 6.  
 6 
Certain products of PHT cells, for example C19MC miRNA’s, are unique to pregnancy and are 
only expressed at high levels during the course of pregnancy. C19MC miRNA levels in the blood 
decline 24hrs after birth and are therefore likely a mechanism of protection for the unborn fetus. 
The C19MC is the largest cluster of miRNAs in the human genome7 and the components of 
PHTCM that carry them are the exosomes. PHT-derived C19MC miRNA–containing exosomes 
may target a subpopulation of maternal cells and cause antiviral responses such as autophagy6.  
Since RVF is known to cause extensive fetal loss in animals, and it has the potential for 
fetal infection in humans, it is important to investigate the interaction between placental 
trophoblast cells and the virus.  
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
The aim of project will be to create a representative model for the transmissibility of 
RVFV across the placenta during pregnancy. By using media that has been conditioned on 
primary human trophoblast cells, we can test our hypothesis that Rift Valley Fever Virus is not 
susceptible to the innate antiviral components of placental trophoblast cells. By this reasoning, 
we predict that resistance of RVFV to the antiviral effects of trophoblast cells may be an 
explanation for the fetal loss in pregnant animals and possibly humans.  By infecting cells in the 
presence of PHTCM and using the appropriate controls we can quantify the amount of antiviral 
activity conferred by PHTCM.    
 
 
Aim 1: To quantify the anti viral affect of PHTCM against RVFV.  
We will determine a constant number of cells to be infected as well as the appropriate MOI’s to 
be used. Viral titers will be calculated after RVFV infection of cells in the presence or absence of 
PHTCM by preforming plaque assays and RT-PCR on the supernatants of infected cells. Based 
on our results, we will identify differences in the anti-viral activity of PHTCM between donors 
as well as the cell line that serves as the best model for infection.  
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Aim 2: To determine whether exosomes within PHTCM may contribute to the observed 
antiviral activity. By sonicating the PHTCM in order to destroy the exosomes within it we can determine if the exosomes play a role in conferring viral resistance to the recipient cells.  
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3.0  MATERIALS AND METHODS 
3.1 BIOSAFETY 
All experiments using live ZH501 RVFV were performed in the biosafety level 3+ 
Regional Biocontainment Laboratory (RBL) at the University of Pittsburgh. Powered air 
purifying respirators (PAPRs) were worn for respiratory protection and all work was conducted 
in a class II biosafety cabinet using Vesphene IIse (diluted 1:128, Steris Corporation, cat. 
#646101) as a disinfectant. Work involving MP-12 RVFV was performed under BSL-2 
conditions in a class II biosafety cabinet, using Vesphene IIse (1:128).  
3.2 CELL CULTURE 
Vero E6 and A549 cells were cultured in an incubator set at 37°C and 5% CO2 in 
Dulbecco’s Modified Eagle Medium with 10% fetal bovine serum, 1% penicillin/streptomycin, 
and 1% L-Glutamine. Cells were split with 0.05% trypsin/EDTA every 3 to 4 days upon 
reaching nearly 100% confluence. 1/12 of the total cells were then seeded into a new T-75 cell 
culture flask.  
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3.3 EXPERIMENTAL DESIGN  
We chose a 96 well tissue culture plate so that each infection group could be done in 
triplicate. Each well at 100% confluence would contain about 100,000 cells and a 
hemocytometer was used to ensure that each well was seeded with a uniform quantity of cells. 
Based on the size of the wells and the 22-24 hours doubling times of the cells, it was determined 
that the wells should be seeded with 20,000 cells each.  
Twenty-four hours after seeding cells the original D10 media was removed and replaced 
with 50ul of PHTCM from Dr. Coynes lab or 50ul of D2 media as control. D2 is Dulbecco’s 
Modified Eagle Medium with 2% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-
Glutamine.  
The cells were allowed to interact with the PHTCM for twenty-four hours before they 
were infected with RVFV. The infection groups we chose were MOI’s of 0.1 and 0.01 (10,000 
and 1,000 plaque forming units, respectively) per infection. The MOI’s were diluted from stock 
viruses and delivered in 50µl volumes leaving a total of 100µl per well. The cells were then 
incubated at 37°C and 5% CO2 for forty-eight hours after which the supernatant was harvested, 
diluted to 10-1 in 900ul of D2 media, then frozen at -80°C for future analysis by rt-PCR and 
plaque assay. 
3.4 RNA EXTRACTION 
The frozen supernatants samples from infections were thawed and 100ul was removed 
from each to be inactivated and used for RNA extraction. The 100ul of the samples were added 
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to 900ul of TriReagent. The samples were mixed and allowed to sit for 5 minutes at which point 
the virus was inactivated.  
After inactivation 200ul of chloroform was added to each sample and the tubes were 
mixed by inversion for twenty seconds and then left to sit for 3 minutes. The samples were then 
centrifuged at 12,000 x G for fifteen minutes at 4°C. After centrifugation the clear aqueous phase 
separated and rose to the top. The aqueous phase was then carefully pipeted off and transferred 
to a new tube. 500ul of 70% EtOH was then added to the aqueous phase and vortexed. The 
resulting lysates were then transferred to a viral spin column from a PureLink® Viral RNA/DNA 
Mini Kit. The columns were then washed with the provided wash buffer with ethanol twice and 
then centrifuged again to dry the column. The columns were finally placed in RNase free 
recovery tubes and 40ul of RNase-free water was added to the column. The water was allowed to 
sit for a minute at room temperature and then centrifuged to elute the RNA. The purified RNA 
was stored at -80°C for future analysis by rt-PCR.  
3.5 RT-PCR 
PCR was setup in a 96 well plate and each well was prepared with 20ul of master mix 
containing 62.5% Invitrogen 2x reaction mix, 2.5% RVFV-2912Fwd primer, 2.5% RVFV-
2981Rev primer, 2.5% RVFV-2950-probe, 2.5% Invitrogen Superscripit™III RT/Platinum® 
Taq mix and 27.5% Invitrogen DEPC water. After the master mix was added 5ul of DEPC water 
was added to the no-template control wells and 5ul of each of the standards and unknowns were 
added to the wells in duplicate. The wells were finally sealed with a clear plastic film and placed 
in the rt-PCR machine and run for 40 cycles.  
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3.6 PLAQUE ASSAY 
Vero E6 cells were seeded into 6 well plates with D10 media and were incubated for 24 
hours until reaching >95% confluence. Once the Vero E6 cells reached confluence supernatant 
samples from the initial infection experiments were thawed and serially diluted in D2 media for 
infection. The media on the Vero E6 cells was removed and 200ul of the appropriate infection 
dilution was added. The plates were placed in the 37°C incubator and rocked every 10 minutes 
for an hour. After the 1-hour infection period the infection media was removed and replaced with 
a Nutrient agar. The nutrient agar was comprised of Dulbecco’s 1X minimum essential medium, 
2% FBS, 1.5% HEPES buffer, 1% penicillin/streptomycin and 0.73% SeaKem agrose. After the 
nutrient agar had solidified the plates were allowed to incubate at 37°C and 5% CO2 for 72 
hours. Once the plaques have formed 37% formaldehyde was added to each and left to sit for at 
least 3 hours to completely inactivate the virus. The formaldehyde and agar was then removed 
and the plates were rinsed. Finally 0.1% crystal violet was added to the wells so that plaques 
could be counted and viral titers could be calculated.  
3.7 SONICATION  
Sonication was preformed with a Branson 450 Sonifier and samples of PHTCM were 
sonicated in a high intensity cup horn. The output was 20kHz set at 80% amplitude and our 
sample of PHTCM was sonicated 3 times for 15 seconds each. 
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3.8 STATISTICAL ANALYSIS 
All statistical significance was calculated in Graph Pad Prism version 6.0. Significance 
was determined by a one-way analysis of variance with a Sidak multiple comparisons analysis at 
a 95% confidence interval. 
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4.0  RESULTS 
4.1 AIM 1: TO QUANTIFY THE ANTI VIRAL AFFECT OF PHTCM 
AGAINST RVFV 
There is currently no established in vitro model for trans-placental infection with 
RVFV and it was necessary to develop a protocol for our analysis. The first goal was to choose 
a cell type to create a model for infection. Vero E6 cells are known to be very susceptible to 
RVFV infection and are often used to propagate RVFV stock. The conditioned media is 
cultured on PHT cells that are human in origin and it was uncertain whether or not the 
PHTCM would be able to confer resistance to the Vero E6 cells. The pilot experiment was 
carried out on Vero E6 cells and the PHTCM used was from the first sample received from 
Dr. Carolyn Coyne’s laboratory. MP12 virus, an attenuated vaccine strain, was the first 
RVFV strain used at MOI’s of 0.1 and 0.01 during the initial infection. 
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Figure 1. Determining the antiviral affect of PHTCM1 on the MP12 virus infection of Vero E6 cells 
(P-values were 0.71 for the 0.1 MOI group and 0.97 for the 0.01 MOI group) 
The results shown in Figure 1 represent the viral titers of the supernatants 48 hours after 
the initial infection with MP12 virus. The titers were calculated by plaque assay and each column 
represent triplicate data with blue columns representing infections in the presence of PHTCM1 
and red columns representing the controls. Based on this initial experiment there was no 
significant difference in the infection of Vero E6 cells with or without PHTCM1. There are also 
no observable trends suggesting that PHTCM1 did not have an effect on viral titer. 
Moving forward, we decided to switch from RVFV MP12 to Zh501. The Zh501 strain of 
RVFV was originally isolated from a human patient during the outbreak of 1977 in Egypt18. 
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Figure 2. Determining the antiviral affect of PHTCM1 on the ZH501 virus infection of Vero E6 cells.  
Figure (A) represents viral titer calculated by plaque assay, the P values were 0.53 for the 0.1 
MOI group and 0.06 for the 0.01 MOI group. Figure (B) represents viral titer calculated by RT-
PCR the P values were 0.04 for the 0.1 MOI group and 0.19 for the 0.01 MOI group. 
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Vero E6 cells were infected with RVFV ZH501 with or without PHTCM1 and the results 
shown above in Figure 2a and 2b represent plaque assay and PCR data for the experiment. 
Figure 2a, which represents the plaque assay data, shows no statistically significant differences 
in viral titers on Vero E6 cells with or without PHTCM. Figure 2b, which represents the PCR 
data, shows minimal statistical significance with a P-value of 0.043 in the 0.1 MOI infection 
group and a trend towards reduction in viral titer in the 0.01 MOI group. Based on the data it 
seems as though PHTCM1 is either not able to efficiently confer viral resistance to Vero E6 cells 
or it is not effective against RVFV MP12 and ZH501.  
Our next step in the investigation was to try a new cell type based on the data we had 
collected on Vero E6 cells. We decided this time to use A549 cells which is a human cell line 
and as such may be more receptive to the antiviral components of PHTCM. The conditioned 
media we initially received from Dr. Coyne was not enough for another experiment in triplicate 
so we requested a new sample. It should be noted that this sample, which will be referred to as 
PHTCM2, was from a different donor’s placental cells.  
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Figure 3. Determining the antiviral affect of PHTCM2 on the ZH501 virus infection of A549 cells.  
Figure (A) represents viral titer calculated by plaque assay, the P values were 0.005 for the 0.1 
MOI group and 0.009 for the 0.01 MOI group. Figure (B) represents viral titer calculated by RT-
PCR the P values were 0.006 for the 0.1 MOI group and 0.0005 for the 0.01 MOI group. 
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A549 cells were infected with RVFV ZH501 with or without PHTCM1 and the results 
shown above in Figure 3a and 3b represent plaque assay and PCR data for the experiment. The 
data in figures 3a and 3b both show high levels of statistical significance and nearly a two log 
reductions in viral titer. A two log reduction equates to a 99% reduction in viral titer meaning 
that PHTCM2 was highly effective at inhibiting RVFV on A549 cells. What was not known at 
this point was whether changing the cell type or changing the PHTCM resulted in significant 
viral reduction.  
 Next we wanted to investigate which variable, cell type or PHTCM, impacted the acute 
change in results between experiments 2 and 3. The fact that we did not have any PHTCM1 
remaining to test on A549 cells as a direct comparison of conditioned medias meant that we 
could only change the cell type. By repeating the experiment with Vero E6 cells and PHTCM2 
we can determine which variable is more important to the extent of antiviral activity observed.   
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Figure 4. Determining the antiviral affect of PHTCM2 on the ZH501 virus infection of Vero E6 cells. 
Figure (A) represents viral titer calculated by plaque assay, the P values were 0.005 for the 0.1 
MOI group and 0.024 for the 0.01 MOI group. Figure (B) represents viral titer calculated by RT-
PCR the P values were 0.08 for the 0.1 MOI group and 0.04 for the 0.01 MOI group. 
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Figures 4a and 4b show significant reductions in viral titer in the presence of PHTCM2 
with the exception of the PCR data for the 0.1 MOI group. This data contrasts the results we 
observed in Figures 2a and 2b that looked at Vero E6 cells and PHTCM1. This contrasting result 
would seem to suggest that the PHTCM1 is not as effective as PHTCM2 at conferring viral 
resistance. The comparison between figures 2 and 4 also tells us that PHTCM is able to confer 
resistance to Vero E6 cells.  
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Figure 5. Comparing the effectiveness of PHTCM by cell type. 
Figure (A) represents viral titer calculated by plaque assay, the P values from left to right were 
0.95, 0.08, <0.0001 and <0.0001 Figure (B) represents viral titer calculated by RT-PCR the P 
values from left to right were 0.16, 0.08, 0.012 and 0.001. 
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Figure 5 is a direct comparison of Vero E6 and A549 cells by pooling the data and 
visually demonstrates  the fact that PHTCM most effectively confers resistance to A549 cells. 
A549 cells also appear to be innately more susceptible to infection based on the higher levels of 
virus found in the control groups when compared to Vero E6 controls. Based on the data A549 
cells will be used as our recipient cell type moving forward.  
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Figure 6. Comparing the effectiveness of PHTCM1 vs. 2 on Vero E6 cells. 
Figure (A) represents viral titer calculated by plaque assay, the P values from left to right were 
0.75, 0.006, 0.067 and <0.0001 Figure (B) represents viral titer calculated by RT-PCR the P 
values from left to right were 0.0007, <0.0001, 0.12 and 0.03. 
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Figure 6 shows a direct comparison of the data from all Vero E6 infections because they 
had been tested with both PHTCM1 and 2. The aim of this figure was to identify which PHTCM 
was best able to confer viral resistance. Based on the data PHTCM2 is better able to confer viral 
resistance based on visual trends and, in the case of the 0.01 MOI groups, statistical significance. 
4.2 AIM 2: TO DETERMINE WHETHER EXOSOMES WITHIN PHTCM MAY 
CONTRIBUTE TO THE OBSERVED ANTIVIRAL ACTIVITY. 
 Based on Figures 5 and 6 we can conclude that A549 cells and PHTCM2 will serve as the 
best model for RVFV infection. With a reliable model we next wanted to try to identify a 
component of PHTCM that was contributing to the antiviral activity we had observed. A paper 
published on PHTCM and viral resistance suggested that exosomes present in the PHTCM 
functioned as a mediator in viral resistance. Treating the PHTCM with sonication was shown to 
completely eliminate the antiviral effect of PHTCM6. Sonication uses of ultrasonic frequencies 
too agitate particles within a solution and in this case would have destroyed any exosomes within 
the PHTCM. We wanted to test the exosome mediated antiviral activity in the case of RVFV 
infection so we sonicated a sample of PHTCM2 and set up an experiment with 3 groups: 
PHTCM, PHTCM that had been sonicated and a control with unconditioned D2 media. 
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Figure 7. Determining the role of exosomes in the conferred resistance by PHTCM2. 
0.1 and 0.01 represent MOIs and + or – represents the presence of PHTCM. The +S represents 
sonicated PHTCM. Figure (A) represents viral titer calculated by plaque assay, the P values from 
left to right were 0.99 <0.0001, <0.0001, 0.99 <0.0001 and <0.0001. Figure (B) represents viral 
titer calculated by RT-PCR the P values from left to right were 0.99 <0.055, <0.046, 0.99 
<0.0019, <0.0017. 
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 Figures 7a and 7b represent the data from an experiment in which a sample of PHTCM 
was sonicated and compared with untreated PHTCM and an unconditioned D2 media control. 
The results show a visual trend that does suggest sonicating PHTCM inhibits its ability to confer 
viral resistance. The exosomes are therefore likely to play a role in the inhibition of RVFV 
infection. 
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5.0  DISCUSSION 
Rift Valley Fever Virus remains an important disease of both humans and animals in 
eastern Africa and parts of the Middle East. It is important to study this viral zoonosis because 
the range of the virus is expanding with subtle changes in climate and the ability to be spread by 
new mosquito vectors. The economic loss and disease burden would be extremely high should 
the virus travel further north through the middle east and into Europe. The possibility of the virus 
making its way across the Atlantic Ocean to the United States would also prove to be a 
devastating problem. The potential for this virus to spread to other parts of the world is real and 
therefore it is necessary to take preventative action now by researching vaccines, treatments and 
disease pathology.  
The most dramatic disease outcomes that we see in animals, specifically domesticated 
ruminants, are the abortion storms and juvenile death. Spontaneous abortion can be seen in 
nearly 100% of pregnant animals during an outbreak and the disease is also highly pathogenic in 
juveniles. These kind of epidemic events lead to huge economic losses for farming communities 
and inevitably result in humans coming in contact with the disease. The close interaction of the 
farming communities and their animals means that many of the individuals near an outbreak of 
RVFV will come in to contact with some form of infected materials. The dramatic impact we see 
on young and pregnant animals raises the question of why we don’t see similar disease 
phenotypes in humans. 
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RVFV has been implicated in two published case studies demonstrating vertical 
transmission events but outside of these cases little information exists. There have been 
serological studies on the prevalence of RVFV antibodies in the serum of women, for example 
one study in Mozambique. The researchers took advantage of a nation-wide study of maternal 
morbidity from 1981-83 that collected serum samples. ELISAs were used to look for RVFV IgG 
antibodies in the women’s sera and it was found that mothers experiencing fetal death or 
miscarriage had the same RVFV antibody prevalence as those with normal deliveries. The only 
published data on RVFV outbreaks in Mozambique at the time was a small outbreak among 
cattle in 1969 8. Although there was no correlation found between sera RVFV antibodies and 
fetal death the cohort in the study may not be the most applicable because of a limited history of 
endemic RVFV.  
Conditioned medium from Primary Human Trophoblast cells is broadly antiviral, 
inhibiting infection by viruses known to cause perinatal infection in human beings. The viral 
resistance can also be conferred to nontrophoblast cells by exposing them to PHTCM19.  For 
these reasons we felt that using PHTCM would create a good model for vertical transmission 
events associated with RVFV infection.  
Vero E6 cells are commonly used to passage RVFV as the virus easily infects them and 
we thought that they would be a good place to start. Our initial experiment was designed to 
investigate the ability of PHTCM to confer resistance to Vero E6 cells when infected with RVFV 
MP12 but the results were inconclusive. MOI’s of both 0.1 and 0.01 resulted in no significant 
differences in viral titer by plaque assay coinciding with our initial hypothesis that The question 
that arose was whether the PHTCM was failing to confer resistance to the Vero E6 cells or if 
RVFV was not susceptible to the type of resistance being conferred by PHTCM1.  
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The next step in investigating our hypothesis was to change our virus from MP12 to the 
fully virulent ZH501 strain. There was a possibility that the PHTCM1 could act on virulence 
factors of RVFV ZH501 that are not present in RVFV MP12. The results of this experiment were 
similar in terms of viral inhibition and ZH501 was shown to be clearly more virulent as titers 
increased by a log and a half.  Interestingly our PCR data showed a visual trend toward viral 
inhibition and the difference in the 0.1 MOI group was minimally statistically significant. 
Because RVFV did not seem to be affected by the PHTCM1 on Vero E6 cells regardless of virus 
strain we wanted to see if a different cell line would show similar results. We wanted to change 
the cell type because there was still the possibility that the viral resistance from PHTCM was not 
being effectively conferred to Vero E6 cells.  
A549 cells are human lung adenocarcinoma cells and we thought they might respond to 
the human PHTCM more effectively than the African green monkey Vero E6 cells. We set up 
our experiment with the A549 cells this time but we had to request a new sample of PHTCM as 
well since we had depleted the original. The parameters for the experiment were the same with 
the exception of cell type and PHTCM batch but the results were dramatically different. This 
time we were able to show a nearly 2 log, or 99%, reduction in viral titer in the presence of 
PHTCM. All of the data by plaque assay and PCR was very significant and demonstrated very 
clearly that PHTCM2 can effectively confer viral resistance to A549 cells. This was the first 
evidence that went against our hypothesis. Because we changed two variables, PHTCM batch 
and cell type in the last experiment we wanted to identify which variable played the biggest role 
in the change of result. Unfortunately we couldn’t go back to PHTCM1 as our supply had been 
exhausted so we went back to Vero E6 cells this time with PHTCM2.  
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The results of our experiment with Vero E6 cells and PHTCM2 were much different from 
the first experiment with PHTCM1. This time viral resistance was conferred to Vero E6 cells 
albeit to a lesser extent than with A549 cells. About a half a log reduction was observed across 
plaque assay and rt-PCR results. The results were, for the most part, significant with the 
exception of the PCR data for the 0.1 MOI group. This failure to achieve significance can be 
attributed to a slight outlier in the data set however. The results of this experiment suggested two 
things; first that PHTCM2 outperforms PHTCM1 and second that PHTCM overall is better able 
to confer viral resistance to A549 cells than Vero E6 cells. Figures 5 and 6 are shown in the 
results specifically to highlight this point through direct comparisons of all the data.  
We felt confident that we had established a model for infection that clearly disproved our 
hypothesis. The fact that PHTCM is able to reduce viral titer by 99% in vitro could be 
demonstrating the reason why we have not seen many vertical transmission events in humans up 
until this point. The fact remains that vertical transmission and abortion is a very prominent 
disease phenotype in some animal species, and therefore must be unique characteristics of the 
human placenta which protects the fetus.  
The literature on PHTCM has demonstrated that a specific cluster of miRNAs on 
Chromosome 19, which is unique to humans, could be responsible for the protective antiviral 
activity in vivo. Exosomes containing these miRNAs can be found circulating in maternal and 
fetal blood supplies throughout pregnancy. The levels of these endosomes quickly drops off after 
birth, which is another finding supporting the protective role of the endosomes. This mechanism 
in vivo could be similar to the mechanism we see in vitro which allows viral resistance to be 
conferred to other cells against RVFV. We now wanted to see if endosomes played a role in the 
antiviral activity of PHTCM against RVFV in our experiments. To test the role of endosomes in 
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the ability of PHTCM to confer resistance we used sonication. Pretreating PHTCM with 
sonication destroys the exosomes present in the PHTCM and should interfere with its ability to 
confer resistance.  
The results shown in Figure 7 demonstrate that sonicated PHTCM losses some of its 
ability to confer viral resistance to A549 cells but not significantly. The data can only be 
interpreted as suggestive here but it would seem to indicate that exosomes do play a role in 
conferring resistance against RVFV. The data also suggests that there are other components of 
the PHTCM that also play a limited role. It should be noted that in experiments preformed by 
Delorme-Axford et al., sonication completely abolished the antiviral effect of PHTCM against 
VSV 6. The mechanism for the antiviral activity of PHTCM may be virus specific and in the case 
of RVFV it may not be mediated exclusively by the exosomes. The components of PHTCM 
require further investigation as to why they are so effective against a wide range of viruses and 
could be important in understanding why some diseases are vertically transmitted while others 
are not. PHTCM is clearly varies between donors and this could have important real world 
implications in the case of human vertical transmission events. The possibility exits that the 
differences between PHTCM samples we observed were the result of variables in the cell 
culturing process. Other reasons for variations between donors could have something to do with 
an individual’s genetics or even nutrition level but regardless, they need to be investigated 
further.  
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